<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00163410</url>
  </required_header>
  <id_info>
    <org_study_id>BY9010/M1-205</org_study_id>
    <nct_id>NCT00163410</nct_id>
  </id_info>
  <brief_title>Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010/M1-205)</brief_title>
  <official_title>A Comparative Study of Inhaled Ciclesonide 200 mcg/Day vs Fluticasone Propionate 200 mcg/Day in Children With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate
      on lung function, symptoms, and use of rescue medication in children with persistent asthma.
      Ciclesonide will be inhaled at one dose level once daily; fluticasone propionate will be
      inhaled at one dose level twice daily. The study duration consists of a baseline period (2 to
      4 weeks) and a treatment period (12 weeks). The study will provide further data on safety and
      tolerability of ciclesonide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 absolute values.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 as % of predicted</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF from spirometry</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diary based morning and evening PEF</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diary based symptom score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diary based salbutamol MDI use</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diurnal PEF fluctuation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drop-out rate due to asthma exacerbations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time until asthma exacerbation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of symptom free- and rescue medication free days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days with asthma control</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical examination</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory work-up</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events.</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  History of persistent bronchial asthma for at least 6 months

          -  FEV1 50-90% of predicted

        Main Exclusion Criteria:

          -  Concomitant severe diseases or diseases which are contraindications for the use of
             inhaled steroids

          -  COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing
             alternating impairment in lung function

          -  Respiratory tract infection or asthma exacerbation within the last 30 days prior to
             entry into the study

          -  History of life-threatening asthma

          -  Premature birth

          -  Current smoking

          -  Smoking history with either equal or more than 10 pack-years

          -  Pregnancy

          -  Intention to become pregnant during the course of the study

          -  Breast feeding

          -  Lack of safe contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380 018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Bangalore</city>
        <zip>560 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Chandigarh</city>
        <zip>160 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Coimbatore, Tamilnadu</city>
        <zip>641 044</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Coimbatore</city>
        <zip>641 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Coimbatore</city>
        <zip>641 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Delhi</city>
        <zip>110 007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Kolkatta</city>
        <zip>700091</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Mumbai</city>
        <zip>400 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Mumbai</city>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Mumbai</city>
        <zip>400 022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Mumbai</city>
        <zip>400 026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Pune</city>
        <zip>411 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Pune</city>
        <zip>411 030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Pune</city>
        <zip>411 033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Shastri Nagar, Jaipur</city>
        <zip>302 016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4525&amp;filename=BY9010_M1-205%20Synopsis.AZCT.com%20posting.pdf</url>
    <description>BY9010_M1-205 Synopsis</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Ciclesonide</keyword>
  <keyword>Child</keyword>
  <keyword>Fluticasone propionate</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

